Sugi Predict

Sugi Predict / Compounds / SCHEMBL787591

SCHEMBL787591

SCHEMBL787591

CCOC(=O)c1cc(Cl)cc(Cl)n1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.51
▸ S1PR2 O95136 1/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ GABRA2 P47869 7/20 0.46
▸ GABRB2 P47870 7/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.45
▸ ALPL P05186 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ POLB P06746 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31127029 1.00 CYP1A2 (0.51) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL3327719 0.91 CYP1A2 (0.61) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL2823510 0.86 CYP1A2 (0.51) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL31078581 0.86 S1PR2 (0.59) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL1179355 0.86 S1PR2 (0.59) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL18137414 0.85 CYP1A2 (0.47) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL3329345 0.85 CYP1A2 (0.54) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL2823270 0.83 CYP1A2 (0.51) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL917429 0.83 CYP1A2 (0.51) CYP1A2S1PR2L3MBTL1GABRA2GABRB2
SCHEMBL18137413 0.82 CYP1A2 (0.47) CYP1A2S1PR2L3MBTL1GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250235-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-08-07 — — US disclosed
US-12319655-B2 RAF kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2025-06-03 — — US disclosed
EP-4444429-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2024-10-16 — — EP disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 — — US disclosed
WO-2023108108-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 — — WO disclosed
EP-3590925-B1 PYRIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA LP (US) 2022-03-30 — — EP disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 — — US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 — — US disclosed
EP-2616441-B1 PYRIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA LP (US) 2019-08-07 — — EP disclosed
EP-2616441-B1 PYRIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA LP (US) 2019-08-07 — — EP disclosed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 — — US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US disclosed
US-20070259849-A1 Azine-Carboxamides as Anti-Cancer Agents ASTRAZENECA AB (SE) 2007-11-08 — — US disclosed
EP-1819341-A2 IL-12 MODULATORY COMPOUNDS Synta Pharmaceuticals Corporation (US) 2007-08-22 — — EP disclosed
EP-1765790-A1 AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT AstraZeneca AB (SE) 2007-03-28 — — EP disclosed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 — — US disclosed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 — — WO disclosed
WO-2006003378-A1 AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT ASTRAZENECA AB (SE) 2006-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223996-A1 IL-12 modulatory compounds IL2, IL4, IFNG CYP1A2 665/4885S1PR2 1106/4885L3MBTL1 4697/4885
US-12319655-B2 RAF kinase inhibitors and methods of use thereof BRAF, RAF1, ARAF CYP1A2 4285/4885S1PR2 2027/4885L3MBTL1 1038/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 CYP1A2 1148/4885S1PR2 859/4885L3MBTL1 4021/4885
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF CYP1A2 4285/4885S1PR2 2027/4885L3MBTL1 1038/4885
US-20070259849-A1 Azine-Carboxamides as Anti-Cancer Agents ARAF, BRAF, RAF1 CYP1A2 1472/4885S1PR2 3323/4885L3MBTL1 4215/4885
US-20250250235-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF CYP1A2 4285/4885S1PR2 2027/4885L3MBTL1 1038/4885
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG CYP1A2 665/4885S1PR2 1106/4885L3MBTL1 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.